Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-β pathway signaling indicates response to primary chemotherapy

Clinical Cancer Research

Volumn 16, Issue 10, 2010, Pages 2852-2860

  Carey, Mark S ^a,b   Agarwal, Roshan ^a,c   Gilks, Blake ^b   Swenerton, Kenneth ^b   Kalloger, Steve ^b   Santos, Jennifer ^b   Ju, Zhenlin ^a   Lu, Yiling ^a   Zhang, Fan ^a   Coombes, Kevin R ^a   Miller, Dianne ^b   Huntsman, David ^b   Mills, Gordon B ^a   Hennessy, Bryan T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN TAZ; PROTEIN YKL 40; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVERSE PHASE PROTEIN ARRAY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77952372145     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2502     Document Type: Article

References (35)

1. du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006;24:1127-1135
2. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
3. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-1329
4. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985;65:264-270 (Pubitemid 15166989)
5. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-1244
6. Zorn KK, Tian C, McGuire WP, et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 2009;115:1028-1035
7. Riedinger JM. Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study. Bull Cancer 2007;94:287-295
8. Prat A, Parera M, Peralta S, et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 2008;19:327-331 (Pubitemid 351201715)
9. Fayers PM, Rustin G, Wood R, et al. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer 1993;3:285-292 (Pubitemid 23290116)
10. Bookman MA. First-line randomized trials: revisiting the Ptolemaic universe. Int J Gynecol Cancer 2008;18 Suppl 1:47-52.
11. Kobel M, Huntsman D, Gilks CB. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med 2008;10:e22.
12. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5:2512-2521 (Pubitemid 44650915)
13. Hennessy BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007;13:7421-7431
14. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007;23:1986-1994 (Pubitemid 47299840)
15. Coombes KR, Wang J, Baggerly KA. Microarrays: retracing steps. Nature medicine 2007;13:1276-7, author reply 7-8.
16. Sabatier R, Finetti P, Cervera N, Birnbaum D, Bertucci F. Gene expression profiling and prediction of clinical outcome in ovarian cancer. Crit Rev Oncol Hematol 2009;72:98-109.
17. Stevens EV, Nishizuka S, Antony S, et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008;7:10-18
18. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311 (Pubitemid 39209661)
19. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005;11:5539-5548 (Pubitemid 41060831)
20. Lee CH, Huntsman DG, Cheang MC, et al. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 2005;24:147-152
21. de Graeff P, Crijns AP, Ten Hoor KA, et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer 2008;99:341-349
22. Li Q, Graff JM, O'Connor AE, Loveland KL, Matzuk MM. SMAD3 regulates gonadal tumorigenesis. Mol Endocrinol (Baltimore, Md) 2007;21:2472-2486
23. Matsuzaki K. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis. Histol Histopathol 2006;21:645-662
24. Millet C, Zhang YE. Roles of Smad3 in TGF-β signaling during carcinogenesis. Crit Rev Eukaryot Gene Expr 2007;17:281-293 (Pubitemid 47015558)
25. Varelas X, Sakuma R, Samavarchi-Tehrani P, et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008;10:837-848 (Pubitemid 351927712)
26. Samarakoon R, Higgins PJ. Integration of non-SMAD and SMAD signaling in TGF-β1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost 2008;100:976-983
27. Koensgen D, Mustea A, Denkert C, Sun PM, Lichtenegger W, Sehouli J. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. Anticancer Res 2006;26:1683-1689
28. Lin SW, Ke FC, Hsiao PW, Lee PP, Lee MT, Hwang JJ. Critical involvement of ILK in TGFβ1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system. Exp Cell Res 2007;313:602-613
29. Do TV, Kubba LA, Du H, Sturgis CD, Woodruff TK. Transforming growth factor-β1, transforming growth factor-β2, and transforming growth factor-β3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res 2008;6:695-705.
30. Looyenga BD, Hammer GD. Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery. Mol Endocrinol (Baltimore, Md) 2007;21:2440-2457
31. Sekimoto G, Matsuzaki K, Yoshida K, et al. Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res 2007;67:5090-5096 (Pubitemid 46997243)
32. Nagata H, Hatano E, Tada M, et al. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology (Baltimore, Md) 2009;49:1944-1953
33. Renlund N, Pieretti-Vanmarcke R, O'Neill FH, Zhang L, Donahoe PK, Teixeira J. c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology 2008;149:108-115
34. Vivas-Mejia P, Benito JM, Fernandez A, et al. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res;16:184-194
35. Riedinger JM, Eche N, Basuyau JP, Dalifard I, Hacene K, Pichon MF. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Gynecol Oncol 2008;109:194-198